From: Clinical and histological evolution after de novo donor-specific anti-human leukocyte antigen antibodies: a single centre retrospective study
N = 13
Rituximab
Plasma exchanges
IVIG
Steroid bolus and treatment reinforcement
yes
no
MVI reduction (n = 6)
3
0
6*
5
1
No change in MVI (=4)
2
MVI progression (n = 3)